News
![knee_x_ray](https://pharmaphorum.com/wp-content/uploads/2022/04/knee_x_ray.jpg)
Ampio slumps as FDA delivers knee osteoarthritis shock
Ampio Pharma's candidate therapy for knee osteoarthritis has been knocked back by the FDA, which will likely now require a new clinical trial of the drug before it will consider a review.